This paper illustrates how comparative effectiveness research can be used by policymakers and health insurers in California to address rising drug costs by aligning spending with the degree of benefit a treatment provides.  ICER received a grant from the California Health Care Foundation (CHCF) to develop the White Paper.

Date of publication: March 2023

For more information, please contact info@icer.org.

Final Documents

White Paper — Applying the Results of Comparative Effectiveness Research to Control Drug Costs: Policy Options for CaliforniaDownload

ICER’s Executive Vice President and Chief Operating Officer, Sarah K. Emond, MPP stated:

“For years, ICER has led a national discussion about how to align the prices in our health care system with the benefits patients receive from various treatments, therapies, and interventions,” said ICER’s Executive Vice President and Chief Operating Officer, Sarah K. Emond, MPP. “Comparative effectiveness research can guide policymakers as they ensure that patients have access to transformative therapies at fair prices. Several states have begun implementing approaches grounded in comparative effectiveness research that are likely to produce meaningful savings and improve access for patients and the health care system.”